Dyne Therapeutics started the new year with proof-of-concept clinical data for experimental genetic medicines addressing two rare muscle diseases—one of which has no FDA-approved treatments. Now the ...
- All Evaluable Patients in the 3.4 mg/kg Cohort Treated with DYNE-101 Q4W Demonstrated Consistent Splicing Correction with a 19% Mean Improvement Across 22-Gene Panel at 3 Months - - Improvement in ...
Dyne Therapeutics’ experimental treatment for Duchenne muscular dystrophy (DMD) showed promise in new data from a small Phase 1/2 trial dubbed DELIVER, the pharma announced this week. The drug, ...
Austin-based Saturn V Capital Management added 1.2 million shares of Dyne Therapeutics during the third quarter. According to a SEC filing for the period ended September 30, Saturn V Capital ...
ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” Q4 2025 ...
- Presentation on ACHIEVE Trial in DM1 and Company Symposium to Feature Data on the Use of Splicing Correction as a Prognostic Biomarker of Functional Outcomes in DM1 - Poster sessions are from 6:00 p ...
WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for ...
Planned submission for U.S. Accelerated Approval of z-rostudirsen on track for Q2 2026; potential launch in Q1 2027 -- Positive topline results ...
Dyne Therapeutics, Inc. has announced that its investigational therapeutic, DYNE-251, for Duchenne muscular dystrophy (DMD), has been granted FDA orphan drug and rare pediatric disease designations.
Monday, Dyne Therapeutics Inc (NASDAQ:DYN) released clinical data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its ongoing Phase 1/2 ...
Dyne Therapeutics (NASDAQ: DYN) was hardly having a bad case of the Mondays. Shares of the clinical-stage biotech were racing more than 9% higher in mid-session action, as the company delivered rather ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results